查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2041715

卡波西氏肉瘤市場預測—按類型、診斷方法、治療方法、最終用戶和地區分類的全球分析—2034年

Kaposi Sarcoma Market Forecasts to 2034 - Global Analysis By Type, Diagnostic Method, Treatment Modality, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

全球卡波西氏肉瘤市場預計到 2026 年將達到 1.25 億美元，並在預測期內以 4.8% 的複合年成長率成長，到 2034 年達到 1.818 億美元。

卡波西肉瘤（KS）是一種罕見的癌症，其特徵是血管異常增生，並在皮膚、黏膜和內臟器官出現病變。它是由人類皰疹病毒8型（HHV-8）感染引起，在免疫系統較弱的人群中更為常見，例如HIV/AIDS患者和接受免疫抑制治療的患者。早期診斷和有效治療對於改善卡波西氏肉瘤患者的預後至關重要。

2022 年 3 月發表在《臨床癌症研究》雜誌上的一項研究得出結論，Pomalidomide是一種安全有效的藥物，可以繞過化療來治療卡波西肉瘤，而與 HIV 感染狀況無關。

愛滋病毒/愛滋病感染率上升

愛滋病毒/愛滋病會削弱免疫系統，使個體更容易罹患卡波西氏肉瘤，這是一種與人類皰疹病毒8型（HHV-8）感染相關的癌症。隨著愛滋病毒/愛滋病在全球的盛行率不斷上升，尤其是在抗逆轉錄病毒療法普及率較低的地區，卡波西氏肉瘤的發生率也隨之增加。這種不斷上升的盛行率推動了對卡波西氏肉瘤早期檢測、診斷和治療的需求，從而促進了針對愛滋病毒/愛滋病患者的疾病管理的治療性介入、診斷工具和支持性護理服務的市場成長。

治療的副作用

卡波西氏肉瘤的治療方法，包括化療、放射線治療和免疫療法，都可能引起嚴重的副作用。這些副作用包括噁心、嘔吐、脫髮和骨髓抑制，可能會影響患者的生活品質和治療順從性。這些副作用不僅影響患者的健康，還可能阻礙治療順從性，導致需要調整劑量或停止治療。因此，患者對卡波西氏肉瘤治療的接受度和使用率可能會下降，從而限制市場成長。

診斷技術的進步

診斷技術的進步顯著加快了卡波西氏肉瘤的早期發現和治療啟動。免疫組織化學和分子檢測等診斷技術的改進，使得卡波西氏肉瘤病灶的識別更加準確快捷，從而能夠更早地進行干預，改善患者預後。此外，生物標記研究的進展也使得風險分層和個人化治療方案的發展成為可能。這些診斷技術的創新正在推動對卡波西氏肉瘤診斷和後續觀察相關診斷工具、影像設備及服務的市場需求成長，並擴大相關市場規模。

治療費用高昂

卡波西氏肉瘤治療費用高昂的主要原因是其治療方法複雜且往往耗時。這些方案可能包括化療、放射線治療、標靶治療和免疫療法，所有這些療法實施起來都非常昂貴，而且通常需要專業的醫學知識。此外，用於控制治療相關副作用的支持性護理也會進一步增加整體成本。高昂的治療費用會限制患者獲得治療的機會，尤其是在醫療資源有限的地區，阻礙市場成長。

新冠疫情的感染疾病

新冠疫情對卡波西氏肉瘤市場產生了多方面的影響。疫情導致醫療系統不堪重負，資源轉移到其他非新冠相關疾病，造成卡波西氏肉瘤的診斷和治療延遲。經濟的不確定性和醫療資源的重新分配也影響了研究經費和藥物研發工作。因此，疫情加劇了卡波西氏肉瘤治療中原有的挑戰，擾亂了患者照護流程和研究活動，阻礙了市場成長。

在預測期內，卡波西氏肉瘤的流行部分預計將是最大的。

預計卡波西氏肉瘤病例將顯著成長。卡波西氏肉瘤是一種在愛滋病流行期間出現的新型肉瘤，主要影響免疫力缺乏的人。它是由人類皰疹病毒8型（HHV-8）感染引起，其特徵是皮膚、黏膜和內臟器官出現大量廣泛性病灶。愛滋病流行，尤其是在高感染率地區，顯著增加了卡波西氏肉瘤的病例數。

在預測期內，化療領域預計將呈現最高的複合年成長率。

在預測期內，化療領域預計將呈現最高的複合年成長率。化療是卡波西氏肉瘤的基石治療方法，尤其適用於晚期和侵襲性病例。最常使用的化療藥物包括脂質體細胞週期蛋白類藥物、紫杉醇和長春花生物鹼。化療旨在縮小或穩定卡波西氏肉瘤腫瘤，緩解症狀，並提高患者的生活品質。研究表明，化療方案能夠延長卡波西氏肉瘤患者的生存期，這正在加速該領域的成長。

市佔率最大的地區：

預計亞太地區將在預測期內佔據最大的市場佔有率。印度和泰國等國家已建立起完善的醫療基礎設施和研究能力。該地區各國政府、醫療機構和製藥公司之間的合作正在改善患者的治療效果。此外，加強擴大抗逆轉錄病毒療法的覆蓋範圍，並意識提升，這些措施正在為亞太地區的卡波西肉瘤市場創造成長機會。

複合年成長率最高的地區：

由於北美地區愛滋病毒/愛滋病感染率高、醫療基礎設施先進且公眾對該疾病的認知不斷提高，預計該地區在預測期內將呈現最高的複合年成長率。該地區成熟的製藥和生物技術產業正致力於提供先進的治療方法並進行卡波西氏肉瘤的臨床試驗。此外，政府的支持性政策、充足的研究經費以及旨在提高公眾對愛滋病毒/愛滋病認知和預防的各項舉措，也進一步推動了市場成長。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域細分
    • 應客戶要求，我們提供主要國家的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

目錄

第1章：執行摘要

第2章：引言

  • 概括
  • 相關利益者
  • 調查範圍
  • 調查方法
  • 研究材料

第3章 市場趨勢分析

  • 促進因素
  • 抑制因子
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • 新冠疫情的感染疾病

第4章：波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的競爭

第5章：全球卡波西氏肉瘤市場：按類型分類

  • 經典型卡波西氏肉瘤
  • 地方性卡波西氏肉瘤
  • 卡波西氏肉瘤
  • 免疫抑制相關性卡波西氏肉瘤
  • 醫源性卡波西氏肉瘤
  • 播散性卡波西氏肉瘤
  • 其他類型

第6章：全球卡波西氏肉瘤市場：依診斷方法分類

  • 組織病理學
  • 免疫組織化學（IHC）
  • 聚合酵素鏈鎖反應（PCR）
  • 切片檢查
  • 其他診斷方法

第7章：全球卡波西氏肉瘤市場：依治療方法

  • 抗逆轉錄病毒療法（ART）
  • 化療
  • 免疫療法
  • 放射線治療
  • 標靶治療
  • 其他治療方法

第8章：全球卡波西氏肉瘤市場：依最終用戶分類

  • 醫院和診所
  • 癌症研究機構
  • 門診手術中心
  • 家庭醫療保健
  • 其他最終用戶

第9章 全球卡波西氏肉瘤市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太國家
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • UAE
    • 卡達
    • 南非
    • 其他中東和非洲國家

第10章 主要發展

  • 合約、夥伴關係、合作關係、合資企業
  • 收購與併購
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第11章：公司簡介

  • Abbott Laboratories
  • AbbVie Inc
  • Biogen Inc
  • Bio-Rad Laboratories
  • Cornell Engineering
  • Celgene Corporation
  • Cipla Limited
  • Eli Lilly and Company
  • Genentech Inc
  • Johnson & Johnson
  • Leo Pharma A/S
  • Merck & Co. Inc
  • Novartis International AG
  • Pfizer Inc
  • Roche Holding AG
  • Siemens Healthineers
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical
  • Thermo Fisher Scientific Inc
  • Vertex Pharmaceuticals Incorporated
Product Code: SMRC25208

According to Stratistics MRC, the Global Kaposi Sarcoma Market is accounted for $125.0 million in 2026 and is expected to reach $181.8 million by 2034 growing at a CAGR of 4.8% during the forecast period. Kaposi Sarcoma (KS) is a rare cancer characterized by abnormal growth of blood vessels and lesions on the skin, mucous membranes, and internal organs. It is caused by infection with human herpesvirus 8 (HHV-8), often affecting individuals with compromised immune systems, such as those with HIV/AIDS or undergoing immunosuppressive therapy. Early diagnosis and effective management are crucial for improving outcomes in patients with Kaposi Sarcoma.

According to the study published in Clinical Cancer Research in March 2022, the study concluded that Pomalidomide is a safe and effective chemotherapy-sparing medication for the treatment of Kaposi sarcoma in people with or without HIV.

Market Dynamics:

Driver:

Growing prevalence of HIV/AIDS

HIV/AIDS weakens the immune system, making individuals more susceptible to developing kaposi sarcoma, a cancer associated with human herpesvirus 8 (HHV-8) infections. As HIV/AIDS prevalence raises globally, particularly in regions with limited access to antiretroviral therapy, the incidence of Kaposi sarcoma increases accordingly. This heightened prevalence drives demand for early detection, diagnosis, and treatment of Kaposi sarcoma, fueling market growth for therapeutic interventions, diagnostic tools, and supportive care services aimed at managing the disease in HIV/AIDS-affected populations.

Restraint:

Side effects of therapy

The therapies for kaposi sarcoma, including chemotherapy, radiation therapy, and immunotherapy, can lead to significant side effects. They may cause nausea, vomiting, hair loss, and bone marrow suppression, compromising patients' quality of life and treatment adherence. These side effects not only impact patient well-being but also deter treatment compliance and may necessitate dose adjustments or discontinuation, thereby limiting the market growth by reducing patient acceptance and adoption of kaposi sarcoma therapies.

Opportunity:

Advancements in diagnosis

Advancements in diagnosis significantly enhance early detection and treatment initiation. Improved diagnostic techniques such as immunohistochemistry and molecular testing enable more accurate and timely identification of kaposi sarcoma lesions, leading to earlier interventions and better patient outcomes. Additionally, advances in biomarker research facilitate risk stratification and personalized therapy approaches. These diagnostic innovations expand the market by increasing the demand for diagnostic tools, imaging equipment, and ancillary services related to kaposi sarcoma diagnosis and monitoring.

Threat:

High cost of treatment

Kaposi Sarcoma's high cost of treatment is primarily attributed to the complex and often prolonged therapeutic regimens involved. These regimens may include chemotherapy, radiation therapy, and targeted or immunotherapy, which are costly to administer and often require specialized medical expertise. Additionally, supportive care to manage treatment-related side effects further adds to the overall treatment expenses. The high cost of treatment can limit access to care, particularly in regions with limited healthcare resources, thereby hampering market growth.

Covid-19 Impact

The covid-19 pandemic has had a multifaceted impact on the kaposi sarcoma market. Healthcare systems strained by the pandemic diverted resources away from non-covid-related conditions, leading to delays in Kaposi sarcoma diagnosis and treatment. Economic uncertainties and healthcare resource reallocations also affected research funding and drug development efforts. Consequently, the pandemic exacerbated existing challenges in kaposi sarcoma management and impeded market growth by disrupting patient care pathways and research endeavours.

The epidemic kaposi sarcoma segment is expected to be the largest during the forecast period

The epidemic kaposi sarcoma segment is estimated to have a lucrative growth. Epidemic Kaposi Sarcoma refers to a form of KS that emerged during the HIV/AIDS epidemic, predominantly affecting immunocompromised individuals. It is caused by human herpes virus 8 (HHV-8) infections and is characterized by the development of multiple, often widespread, lesions on the skin, mucous membranes, and internal organs. The HIV/AIDS epidemic, particularly in regions with high prevalence, significantly contributed to the rise of epidemic KS cases.

The chemotherapy segment is expected to have the highest CAGR during the forecast period

The chemotherapy segment is anticipated to witness the highest CAGR growth during the forecast period. Chemotherapy is a cornerstone treatment for Kaposi Sarcoma, particularly in advanced or aggressive cases. The most commonly used chemotherapy agents include liposomal anthracyclines, paclitaxel, and vinca alkaloids. Chemotherapy aims to shrink or stabilize KS tumors, alleviate symptoms, and improve quality of life. Chemotherapy regimens have been shown to extend survival in KS patients which is accelerating the segment growth.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period. Countries like India and Thailand have established strong healthcare infrastructure and research capabilities. Collaboration between governments, healthcare organizations and pharmaceutical companies in the region are improving patient outcomes. Further, increasing efforts to expand access to antiretroviral therapy, and raise awareness about HIV/AIDS and related cancers offer growth opportunities for the Kaposi Sarcoma market in Asia Pacific.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period, owing to the high prevalence of HIV/AIDS, advanced healthcare infrastructure, and increasing awareness about the disease. The region's well-established pharmaceutical and biotechnology industries contribute to the availability of advanced treatment options and clinical trials for Kaposi Sarcoma. Additionally, supportive government policies, robust research funding, and initiatives promoting HIV/AIDS awareness and prevention further bolster market growth.

Key players in the market

Some of the key players profiled in the Kaposi Sarcoma Market include Abbott Laboratories, AbbVie Inc, Biogen Inc, Bio-Rad Laboratories, Cornell Engineering, Celgene Corporation, Cipla Limited, Eli Lilly and Company, Genentech Inc, Johnson & Johnson, Leo Pharma A/S, Merck & Co. Inc, Novartis International AG, Pfizer Inc, Roche Holding AG, Siemens Healthineers, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical, Thermo Fisher Scientific Inc and Vertex Pharmaceuticals Incorporated.

Key Developments:

In August 2022, Researchers at Cornell Engineering and Weill Cornell Medicine designed a portable diagnostic device that has been deployed in clinical tests in Uganda to identify cases of Kaposi sarcoma. This common yet difficult-to-detect cancer often signals the presence of HIV infection.

Types Covered:

  • Classic Kaposi Sarcoma
  • Endemic Kaposi Sarcoma
  • Epidemic Kaposi Sarcoma
  • Immunosuppression-Associated Kaposi Sarcoma
  • Latrogenic Kaposi Sarcoma
  • Disseminated Kaposi Sarcoma
  • Other Types

Diagnostic Methods Covered:

  • Histopathology
  • Immunohistochemistry (IHC)
  • Polymerase Chain Reaction (PCR)
  • Biopsy
  • Other Diagnostic Methods

Treatment Modalities Covered:

  • Antiretroviral Therapy (ART)
  • Chemotherapy
  • Immunotherapy
  • Radiation Therapy
  • Targeted Therapy
  • Other Therapies

End Users Covered:

  • Hospitals & Clinics
  • Cancer Research Institutions
  • Ambulatory Surgical Centers
  • Home Healthcare
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Kaposi Sarcoma Market, By Type

  • 5.1 Introduction
  • 5.2 Classic Kaposi Sarcoma
  • 5.3 Endemic Kaposi Sarcoma
  • 5.4 Epidemic Kaposi Sarcoma
  • 5.5 Immunosuppression-Associated Kaposi Sarcoma
  • 5.6 Latrogenic Kaposi Sarcoma
  • 5.7 Disseminated Kaposi Sarcoma
  • 5.8 Other Types

6 Global Kaposi Sarcoma Market, By Diagnostic Method

  • 6.1 Introduction
  • 6.2 Histopathology
  • 6.3 Immunohistochemistry (IHC)
  • 6.4 Polymerase Chain Reaction (PCR)
  • 6.5 Biopsy
  • 6.6 Other Diagnostic Methods

7 Global Kaposi Sarcoma Market, By Treatment Modality

  • 7.1 Introduction
  • 7.2 Antiretroviral Therapy (ART)
  • 7.3 Chemotherapy
  • 7.4 Immunotherapy
  • 7.5 Radiation Therapy
  • 7.6 Targeted Therapy
  • 7.7 Other Therapies

8 Global Kaposi Sarcoma Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals & Clinics
  • 8.3 Cancer Research Institutions
  • 8.4 Ambulatory Surgical Centers
  • 8.5 Home Healthcare
  • 8.6 Other End Users

9 Global Kaposi Sarcoma Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Abbott Laboratories
  • 11.2 AbbVie Inc
  • 11.3 Biogen Inc
  • 11.4 Bio-Rad Laboratories
  • 11.5 Cornell Engineering
  • 11.6 Celgene Corporation
  • 11.7 Cipla Limited
  • 11.8 Eli Lilly and Company
  • 11.9 Genentech Inc
  • 11.10 Johnson & Johnson
  • 11.11 Leo Pharma A/S
  • 11.12 Merck & Co. Inc
  • 11.13 Novartis International AG
  • 11.14 Pfizer Inc
  • 11.15 Roche Holding AG
  • 11.16 Siemens Healthineers
  • 11.17 Takeda Pharmaceutical Company Limited
  • 11.18 Teva Pharmaceutical
  • 11.19 Thermo Fisher Scientific Inc
  • 11.20 Vertex Pharmaceuticals Incorporated

List of Tables

  • Table 1 Global Kaposi Sarcoma Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Kaposi Sarcoma Market Outlook, By Type (2023-2034) ($MN)
  • Table 3 Global Kaposi Sarcoma Market Outlook, By Classic Kaposi Sarcoma (2023-2034) ($MN)
  • Table 4 Global Kaposi Sarcoma Market Outlook, By Endemic Kaposi Sarcoma (2023-2034) ($MN)
  • Table 5 Global Kaposi Sarcoma Market Outlook, By Epidemic Kaposi Sarcoma (2023-2034) ($MN)
  • Table 6 Global Kaposi Sarcoma Market Outlook, By Immunosuppression-Associated Kaposi Sarcoma (2023-2034) ($MN)
  • Table 7 Global Kaposi Sarcoma Market Outlook, By Latrogenic Kaposi Sarcoma (2023-2034) ($MN)
  • Table 8 Global Kaposi Sarcoma Market Outlook, By Disseminated Kaposi Sarcoma (2023-2034) ($MN)
  • Table 9 Global Kaposi Sarcoma Market Outlook, By Other Types (2023-2034) ($MN)
  • Table 10 Global Kaposi Sarcoma Market Outlook, By Diagnostic Method (2023-2034) ($MN)
  • Table 11 Global Kaposi Sarcoma Market Outlook, By Histopathology (2023-2034) ($MN)
  • Table 12 Global Kaposi Sarcoma Market Outlook, By Immunohistochemistry (IHC) (2023-2034) ($MN)
  • Table 13 Global Kaposi Sarcoma Market Outlook, By Polymerase Chain Reaction (PCR) (2023-2034) ($MN)
  • Table 14 Global Kaposi Sarcoma Market Outlook, By Biopsy (2023-2034) ($MN)
  • Table 15 Global Kaposi Sarcoma Market Outlook, By Other Diagnostic Methods (2023-2034) ($MN)
  • Table 16 Global Kaposi Sarcoma Market Outlook, By Treatment Modality (2023-2034) ($MN)
  • Table 17 Global Kaposi Sarcoma Market Outlook, By Antiretroviral Therapy (ART) (2023-2034) ($MN)
  • Table 18 Global Kaposi Sarcoma Market Outlook, By Chemotherapy (2023-2034) ($MN)
  • Table 19 Global Kaposi Sarcoma Market Outlook, By Immunotherapy (2023-2034) ($MN)
  • Table 20 Global Kaposi Sarcoma Market Outlook, By Radiation Therapy (2023-2034) ($MN)
  • Table 21 Global Kaposi Sarcoma Market Outlook, By Targeted Therapy (2023-2034) ($MN)
  • Table 22 Global Kaposi Sarcoma Market Outlook, By Other Therapies (2023-2034) ($MN)
  • Table 23 Global Kaposi Sarcoma Market Outlook, By End User (2023-2034) ($MN)
  • Table 24 Global Kaposi Sarcoma Market Outlook, By Hospitals & Clinics (2023-2034) ($MN)
  • Table 25 Global Kaposi Sarcoma Market Outlook, By Cancer Research Institutions (2023-2034) ($MN)
  • Table 26 Global Kaposi Sarcoma Market Outlook, By Ambulatory Surgical Centers (2023-2034) ($MN)
  • Table 27 Global Kaposi Sarcoma Market Outlook, By Home Healthcare (2023-2034) ($MN)
  • Table 28 Global Kaposi Sarcoma Market Outlook, By Other End Users (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.